HALOBETASOL PROPIONATE

Post-LOE

halobetasol propionate

Design Pharmaceuticals

ANDATOPICALAEROSOL, FOAM

Approved

Aug 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

HALOBETASOL PROPIONATE (halobetasol propionate) by Design Pharmaceuticals is signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown. Approved for psoriasis. First approved in 2023.

Drug data last refreshed 20h ago

$0.0BPart D

Mechanism of Action

signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown.

Indications (1)

psoriasis

Clinical Trials (1)

NCT04720105Phase 4Completed

Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

Started Nov 2020

22 enrolled

Palmoplantar PsoriasisPlaque Psoriasis

Company

Worked on HALOBETASOL PROPIONATE at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.